全文获取类型
收费全文 | 15279篇 |
免费 | 1324篇 |
国内免费 | 460篇 |
专业分类
耳鼻咽喉 | 168篇 |
儿科学 | 279篇 |
妇产科学 | 376篇 |
基础医学 | 1988篇 |
口腔科学 | 319篇 |
临床医学 | 1758篇 |
内科学 | 2699篇 |
皮肤病学 | 308篇 |
神经病学 | 1052篇 |
特种医学 | 625篇 |
外国民族医学 | 3篇 |
外科学 | 1901篇 |
综合类 | 1129篇 |
一般理论 | 2篇 |
预防医学 | 977篇 |
眼科学 | 436篇 |
药学 | 1375篇 |
4篇 | |
中国医学 | 335篇 |
肿瘤学 | 1329篇 |
出版年
2023年 | 153篇 |
2022年 | 179篇 |
2021年 | 482篇 |
2020年 | 318篇 |
2019年 | 413篇 |
2018年 | 403篇 |
2017年 | 371篇 |
2016年 | 356篇 |
2015年 | 518篇 |
2014年 | 620篇 |
2013年 | 682篇 |
2012年 | 1116篇 |
2011年 | 1186篇 |
2010年 | 711篇 |
2009年 | 596篇 |
2008年 | 870篇 |
2007年 | 846篇 |
2006年 | 816篇 |
2005年 | 764篇 |
2004年 | 693篇 |
2003年 | 595篇 |
2002年 | 519篇 |
2001年 | 462篇 |
2000年 | 391篇 |
1999年 | 386篇 |
1998年 | 141篇 |
1997年 | 137篇 |
1996年 | 167篇 |
1995年 | 145篇 |
1994年 | 106篇 |
1993年 | 85篇 |
1992年 | 194篇 |
1991年 | 182篇 |
1990年 | 156篇 |
1989年 | 134篇 |
1988年 | 127篇 |
1987年 | 106篇 |
1986年 | 105篇 |
1985年 | 103篇 |
1984年 | 76篇 |
1983年 | 70篇 |
1982年 | 56篇 |
1981年 | 55篇 |
1980年 | 45篇 |
1979年 | 60篇 |
1978年 | 50篇 |
1977年 | 33篇 |
1975年 | 27篇 |
1974年 | 43篇 |
1968年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 265 毫秒
1.
2.
帕金森病是以多巴胺能神经元减少导致的以静止性震颤、肌强直、运动迟缓和姿势步态障碍为主要临床症状的疾病。此病是蒙医白脉病的一种,又称彻彻热乎病。蒙医将人体的脉络分为白脉和黑脉。白脉病是白脉系统遭受致病因素的影响后所致的一系列疾病的总称,临床上很多疾病归属于“白脉病”。为更好的实现对蒙医优势单病种的规范化研究,本文基于白脉理论,探析蒙医对帕金森病的认识,以期为未来的研究提供理论支持。 相似文献
3.
Derek K. Chu Romina Brignardello-Petersen Gordon H. Guyatt Cristian Ricci Jon Genuneit 《Pediatric allergy and immunology》2022,33(1):e13609
Network meta-analyses (NMAs) simultaneously estimate the effects of multiple possible treatment options for a given clinical presentation. For allergists to benefit optimally from NMAs, they must understand the process and be able to interpret the results. Through a worked example published in Pediatric Allergy and Immunology, we summarize how to identify credible NMAs and interpret them with a focus on recent innovations in the GRADE approach (Grading of Recommendations Assessment, Development, and Evaluation). NMAs build on traditional systematic reviews and meta-analyses that consider only direct paired comparisons by including indirect evidence, thus allowing the simultaneous assessment of the relative effect of all pairs of competing alternatives. Our framework informs clinicians of how to identify credible NMAs and address the certainty of the evidence. Trustworthy NMAs fill a critical gap in providing key inferences using direct and indirect evidence to inform clinical decision making when faced with more than two competing courses of treatment options. This document will help allergists to identify trustworthy NMAs to enhance patient care. 相似文献
4.
Kerryn W. Reding Aaron K. Aragaki Richard K. Cheng Ana Barac Sylvia Wassertheil-Smoller Jessica Chubak Marian C. Limacher W. Gregory Hundley Ralph D'Agostino Jr. Mara Z. Vitolins Theodore M. Brasky Laurel A. Habel Eric J. Chow Rebecca D. Jackson Chu Chen April Morgenroth Wendy E. Barrington Matthew Banegas Matthew Barnhart Rowan T. Chlebowski 《The oncologist》2020,25(8):712-721
5.
Youjin Kim Chu Hyun Kim Ho Yun Lee Se-Hoon Lee Hong Sook Kim Sook Lee Hongui Cha Sungjun Hong Kyunga Kim Sang Won Seo Jong-Mu Sun Myung-Ju Ahn Jin Seok Ahn Keunchil Park 《Journal of thoracic oncology》2019,14(9):1608-1618
IntroductionHyperprogressive disease (HPD), characterized by accelerated tumor progression, has been proposed as a new pattern of progression after immune checkpoint inhibitor (ICI) treatment. The aim of this study was to describe the characteristics of HPD and investigate its predictive markers.MethodsClinical and radiological findings of 335 patients with advanced NSCLC treated with ICI monotherapy were retrospectively analyzed. Radiological data were quantitatively and longitudinally analyzed for tumor size and volume by comparing baseline and follow-up computerized tomography results. The findings were matched with individual genomic profiles generated by deep sequencing of 380 genes.ResultsAmong 135 patients with progressive disease (PD), as assessed by the Response Evaluation Criteria in Solid Tumors version 1.1 criteria, 48 (14.3% of all patients and 35.6% of those with PD) and 44 (13.1% of all patients and 32.6% among those with PD) were found to have HPD by volumetry (HPDV) and assessed by RECIST 1.1 (HPDR), respectively. Patients with HPDV were associated with significantly inferior overall survival (OS) versus that of patients without HPDV with PD (median OS = 4.7 months [95% confidence interval: 3.5–11.9)] versus 7.9 months [95% confidence interval: 6.0–13.5] [p = 0.004]); OS did not differ between patients without and without HPDR. HPDV status was an independent factor in OS. A derived neutrophil-to-lymphocyte ratio greater than 4 and lactate dehydrogenase level greater than the upper limit of normal were significantly associated with HPDV. Moreover, we identified coinciding KRAS and serine/threonine kinase 11 gene (STK11) mutations in the cohort of patients with HPDV (three of 16), whereas none were found in the cohort of patients without HPDV (zero of 28).ConclusionsDefining HPD treated with ICI on the basis of volumetric measurement is more precise than is defining it on the basis of one-dimensional analysis. Pre-ICI derived neutrophil-to-lymphocyte ratio, lactate dehydrogenase level, and concurrence of STK11 and KRAS mutations could thus be used as potential biomarkers for HPD prediction. 相似文献
6.
目的:探讨对携带BRCA1/2突变的中国健康女性实施乳腺预防性切除及I期重建的可行性。方法:选择2018年1月至2019年2月3例于北京大学国际医院就诊的携带BRCA1/2突变的中国健康女性,其中2例携带BRCA1突变、1例携带BRCA2突变,均有乳腺癌家族史,年龄为34~36岁,实施预防性保留乳头-乳晕的双侧乳腺切除和Ⅰ期假体重建术。结果:3例患者术后无并发症发生,术后中位随访时间为18个月,均无乳腺癌发生,对重建乳房外形满意,且焦虑和恐惧情绪显著下降,取得良好的疗效。结论:对携带BRCA1/2突变且有乳腺癌家族史的中国健康女性,在严格筛选的基础上,可慎重开展乳腺预防性切除及Ⅰ期重建术。 相似文献
7.
Daniel Shepshelovich Wei Xu Lin Lu Aline Fares Ping Yang David Christiani Jie Zhang Kouya Shiraishi Brid M. Ryan Chu Chen Ann G. Schwartz Adonina Tardon Xifeng Wu Matthew B. Schabath M. Dawn Teare Loic Le Marchand Zuo-Feng Zhang John K. Field Rayjean J. Hung 《Journal of thoracic oncology》2019,14(9):1594-1607
IntroductionThe relationships between morbid obesity, changes in body mass index (BMI) before cancer diagnosis, and lung cancer outcomes by histology (SCLC and NSCLC) have not been well studied.MethodsIndividual level data analysis was performed on 25,430 patients with NSCLC and 2787 patients with SCLC from 16 studies of the International Lung Cancer Consortium evaluating the association between various BMI variables and lung cancer overall survival, reported as adjusted hazard ratios (aHRs) from Cox proportional hazards models and adjusted penalized smoothing spline plots.ResultsOverall survival of NSCLC had putative U-shaped hazard ratio relationships with BMI based on spline plots: being underweight (BMI < 18.5 kg/m2; aHR = 1.56; 95% confidence interval [CI]:1.43–1.70) or morbidly overweight (BMI > 40 kg/m2; aHR = 1.09; 95% CI: 0.95–1.26) at the time of diagnosis was associated with worse stage-specific prognosis, whereas being overweight (25 kg/m2 ≤ BMI < 30 kg/m2; aHR = 0.89; 95% CI: 0.85–0.95) or obese (30 kg/m2 ≤ BMI ≤ 40 kg/m2; aHR = 0.86; 95% CI: 0.82–0.91) was associated with improved survival. Although not significant, a similar pattern was seen with SCLC. Compared with an increased or stable BMI from the period between young adulthood until date of diagnosis, a decreased BMI was associated with worse outcomes in NSCLC (aHR = 1.24; 95% CI: 1.2–1.3) and SCLC patients (aHR=1.26 (95% CI: 1.0–1.6). Decreased BMI was consistently associated with worse outcome, across clinicodemographic subsets.ConclusionsBoth being underweight or morbidly obese at time of diagnosis is associated with lower stage-specific survival in independent assessments of NSCLC and SCLC patients. In addition, a decrease in BMI at lung cancer diagnosis relative to early adulthood is a consistent marker of poor survival. 相似文献
8.
9.